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Summary and Implications 
Ceftiofur is the most commonly used antimicrobial in 
lactating dairy cows. Recently, there has been an increase in 
the number of violative residues of ceftiofur in the tissues of 
cull dairy cows. This was the first project in a series of 
projects we will be completing aimed at characterizing the 
pharmacokinetics of ceftiofur in disease challenged animals. 
The results of this study indicate that diseased animals have 
lower plasma concentrations and altered pharmacokinetics 
compared to healthy animals. Future work will investigate 
the influence of altered pharmacokinetics on the presence of 
violative residues. 
  
Introduction 
Mastitis is a frequent problem among dairy cows, 
reducing milk yield and increasing cull rates. Systemic 
therapy with the cephalosporin antimicrobial ceftiofur 
hydrochloride (CEF) may improve therapeutic outcomes, 
but the incidence of CEF violative residues has increased 
annually since 2011. One potential explanation is that 
disease status may alter the pharmacokinetics (PK) of CEF. 
To test this hypothesis, we compared the plasma PK of CEF 
in healthy cows with those with severe endotoxic mastitis. 
 
Materials and Methods 
Eight cows with naturally occurring mastitis and eight 
clinically healthy cows were treated with 2.2 mg of ceftiofur 
hydrochloride/kg of body weight once daily for five days 
via the intramuscular route. Blood was collected at 0, 0.33, 
0.67, 1, 1.5, 2, 3, 4, 8, 16, and 24 hours after the first 
ceftiofur administration and every eight hours thereafter 
until 120 hours after the final dose. Plasma samples were 
analyzed for ceftiofur concentrations using liquid 
chromatography coupled with mass spectrometry. Ceftiofur 
concentrations are reported as total ceftiofur, which includes 
the parent compound and all metabolites. Single dose and 
multi-dose non-compartmental pharmacokinetic models 
were determined for both groups. Statistical analysis was 
performed using SAS 9.4 (SAS Institute, Cary, NC). All PK 
data are reported as geometric means. Disease and control 
groups were compared using the Wilcoxon two-sample 
rank-sum test (Mann-Whitney test). Multiple variables (i. e. 
drug concentrations and PK values) had distributions that 
were right skewed with long tails. Therefore, non-
parametric methods were used to analyze the data in this 
situation.  Statistical significance was established when P < 
0.05. 
 
Results and Discussion 
Compared to control cows, the disease group had an 
initially higher peak concentration, a higher volume of 
distribution and drug clearance rates. The disease group also 
had a lower area under the curve per dosing interval, steady 
state concentration maximum, and dose-adjusted peak 
steady state concentration. All other PK parameters were not 
different between the two groups.  
These data show that significant PK changes occur in 
diseased animals administered CEF relative to healthy, 
control animals. These outcomes potentially have public 
health significance in that: 1) drug efficacy could be lower 
than expected; 2) there may be an increase in violative drug 
residues in tissues of cull animals or milk; and 3) this may 
lead to increases in antimicrobial resistance. This body of 
evidence suggests that the drug approval process should be 
changed such that the physiological changes of health-
challenged cows are addressed. It does not, however, lead to 
any conclusions regarding the outcomes of treating health-
challenged cows nor the contribution of altered PK on the 
increasing violative CEF residues found in culled dairy 
cattle. Further work examining tissue distribution depletion 
of drugs and their influence on residue levels in diseased 
animals at the end of their withdrawal periods is necessary 
to more thoroughly characterize this problem.  
